Cipher Pharmaceuticals

219 articles with Cipher Pharmaceuticals

• Cipher Pharma Reports Q2 2016 Results Highlighted By 32% Revenue Growth And $3.1 Million Cash From Operations

  8/10/2016

• Cipher Pharma Shakes Up Board as Four Members Step Down, Effective Immediately

  8/9/2016

• Cipher Pharma Announces Preliminary Q2 2016 Results Highlighted By 30+% Revenue Growth And $3.0+Million Cash From Operations

  8/3/2016

• Notice Of Cipher Pharma Q2 2016 Conference Call

  7/20/2016

• Cipher Pharma Announces Ozenoxacin Accepted For Review By Health Canada

  7/12/2016

• Special Committee Of Cipher Pharma Responds To Early Warning Report Filed By 1207407 Ontario Limited

  7/6/2016

• Special Committee Of Cipher Pharma Responds To Early Warning Report Filed By 1207407 Ontario Limited

  7/6/2016

• Cipher Pharma Out-Licenses Rights To ASF-1096 For Anorectal Disorders

  6/20/2016

• Cipher Pharma To Present At Two Upcoming U.S. Investor Conferences

  5/31/2016

• Cipher Pharma Reports Voting Results From Annual And Special Meeting Of Shareholders

  5/6/2016

• Cipher Pharma Reports Q1 2016 Financial Results

  5/5/2016

• Cipher Pharma Acquires Worldwide Rights To Dalhousie University's Investigational Tattoo Removal Cream

  5/2/2016

• Notice Of Cipher Pharma Q1 2016 Conference Call & Annual And Special Meeting

  4/25/2016

• Cipher Pharma Announces Retirement Of CFO Norm Evans

  4/22/2016

• Cipher Pharma Proposes Adding Rosemary A. Crane And Dr. Renee P. Tannenbaum To Board Of Directors

  4/7/2016

• Cipher Pharma Announces Approvals Of Astion Acquired Barrier Creams By Health Canada And The Medicines Evaluation Board

  4/7/2016

• Cipher Pharma Announces Canadian Launch Of Beteflam

  4/6/2016

• Cipher Pharma Appoints Ralph Bohrer President & General Manager Of U.S. Business

  3/4/2016

• Cipher Pharma To Present At Two Upcoming Investor Conferences

  3/3/2016

• Cipher Pharma Reports 2015 Financial Results

  2/24/2016